bioMérieux S.A. (BMXXY)

OTCMKTS · Delayed Price · Currency is USD
12.95
0.00 (0.00%)
At close: May 9, 2025
36.17%
Market Cap 15.88B
Revenue (ttm) 4.12B
Net Income (ttm) 447.46M
Shares Out n/a
EPS (ttm) 3.77
PE Ratio 35.49
Forward PE 26.49
Dividend 0.05 (0.39%)
Ex-Dividend Date Jun 10, 2024
Volume 26,310
Average Volume 1,321
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range 9.51 - 12.95
Beta 0.22
RSI 100.00
Earnings Date Sep 4, 2025

About bioMérieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; V... [Read more]

Industry Medical - Specialties
Sector Healthcare
Founded 1963
Employees 14,754
Stock Exchange OTCMKTS
Ticker Symbol BMXXY
Full Company Profile

Financial Performance

In 2024, bioMérieux's revenue was 3.98 billion, an increase of 8.31% compared to the previous year's 3.67 billion. Earnings were 432.20 million, an increase of 20.86%.

Financial numbers in EUR Financial Statements

News

There is no news available yet.